Merck & Co Inc (NYSE:MRK, ETR:6MK) on Thursday reported third quarter 2025 earnings and revenue that surpassed Wall Street expectations, lifted by strong demand for its cancer immunotherapy Keytruda, but reduced its full-year sales outlook to reflect lower estimated tariff costs, among other factors.
The pharmaceutical company’s revenue for the quarter rose 4% year over year to $17.28 billion, exceeding the $16.96 billion analyst consensus estimate provided by LSEG.
Keytruda sales increased 10% to $8.14 billion, just shy of the $8.24 billion anticipated by analysts.
Merck also posted adjusted earnings per share for the period of $2.58, better than the Wall Street forecast of $2.35.
Looking ahead, the company said it now expects 2025 revenue of between $64.5 billion and $65 billion, compared with $64.3 billion to $65.3 billion previously.
Merck also anticipates full year adjusted earnings of between $8.93 and $8.98 per share, compared with its previous outlook of $8.87 to $8.97.
Merck shares slipped 0.3% to $86.32 in late morning trading on Thursday.